Odyssey Therapeutics
NASDAQ: ODTXCambridge, US · Founded 2021 · 7 known investors
Creating next generation precision medicines for patients with cancer and inflammatory diseases by targeting key signaling nodes.
Biotech
Founders & leadership
VO
Valerie OdegardDirector
JC
Jill CarrollDirector
CG
Carl GordonDirector
JL
Jeffrey LeidenDirector
CB
Charles BaumDirector
GD
Gary D GlickExecutive Officer, Director
Investors · 7
Reported raises · per SEC filings
Form D private placements▶$214MraisedDec 2025 · 55 investors · BiotechnologyRule 506(b)
▶$214MraisedDec 2025 · 55 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Valerie OdegardDirector
- Carl GordonDirector
- Carolyn NgDirector
- Gary D. GlickExecutive Officer, Director
- Timothy WalbertDirector
- Paulina HillDirector
- Nan LiDirector
- Jeffrey LeidenDirector
- Jason HaasExecutive Officer
- Nia TatsisDirector
- Ksenija PavleticDirector
- Shelley ChuDirector
- lan F. SmithDirector
- Jill CarrollDirector
- Offering amount
- $214M
- Amount sold
- $214M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$117.2MraisedAug 2024 · 43 investors · BiotechnologyRule 506(b)
▶$117.2MraisedAug 2024 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy WalbertDirector
- Charles M. BaumDirector
- Gary D. GlickExecutive Officer, Director
- Jill CarrollDirector
- Jeffrey LeidenDirector
- Ian SmithDirector
- Valerie OdegardDirector
- Lorence KimDirector
- Carl GordonDirector
- Offering amount
- $121.1M
- Amount sold
- $117.2M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$168MraisedOct 2022 · 34 investors · BiotechnologyRule 506(b)
▶$168MraisedOct 2022 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Valerie OdegardDirector
- Jill CarrollDirector
- Carl GordonDirector
- Jeffrey LeidenDirector
- Charles BaumDirector
- Gary D GlickExecutive Officer, Director
- Offering amount
- $174.9M
- Amount sold
- $168M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$91.6MraisedOct 2021 · 63 investors · BiotechnologyRule 506(b)
▶$91.6MraisedOct 2021 · 63 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carl GordonDirector
- Chuck BaumDirector
- Valerie OdegardDirector
- Gary D GlickExecutive Officer, Director
- Jill CarrollDirector
- Amount sold
- $91.6M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.